scholarly journals Single centre results of first 100 patients treated with the absorb bioresorbable vascular scaffold

2015 ◽  
Vol 24 ◽  
pp. S88
Author(s):  
W. Jaffe ◽  
A. Ko ◽  
D. Scott ◽  
M. Lindesay
Keyword(s):  
Single Centre ◽  
Bioresorbable Vascular Scaffold ◽  
Vascular Scaffold

scholarly journals TCT-426 Three and half year experience of bioresorbable vascular scaffold implantation in routine clinical practice in a single centre in India

2016 ◽  
Vol 68 (18) ◽  
pp. B172 ◽  
Author(s):  
Raghuram Palaparti ◽  
Gopala Krishna Koduru ◽  
Boochi Babu Mannuva ◽  
Somasekhar Ghanta ◽  
Srinivas Chowdary Parvathaneni ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Routine Clinical Practice ◽  
Single Centre ◽  
Bioresorbable Vascular Scaffold ◽  
Vascular Scaffold

scholarly journals The Absorb bioresorbable vascular scaffold in real-world practice: long-term follow-up of the AMC Single Centre Real World PCI Registry

2020 ◽  
Vol 28 (3) ◽  
pp. 153-160 ◽  
Author(s):  
R. Y. G. Tijssen ◽  
M. E. Annink ◽  
R. P. Kraak ◽  
K. T. Koch ◽  
J. Baan Jr ◽  
...  
Keyword(s):  
Real World ◽  
Single Centre ◽  
Bioresorbable Vascular Scaffold ◽  
Vascular Scaffold ◽  
Long Term Follow Up

Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry

2015 ◽  
Vol 10 (11) ◽  
pp. 1160-1168 ◽  
Author(s):  
Robin P. Kraak ◽  
Mariëlla E.C.J. Hassell ◽  
Maik J. Grundeken ◽  
Karel T. Koch ◽  
Jose P.S. Henriques ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Real World ◽  
Initial Experience ◽  
Single Centre ◽  
Bioresorbable Vascular Scaffold ◽  
Vascular Scaffold

scholarly journals Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience

2017 ◽  
Vol 25 (11) ◽  
pp. 611-617
Author(s):  
W. S. Remkes ◽  
R. S. Hermanides ◽  
M. W. Kennedy ◽  
E. Fabris ◽  
E. Kaplan ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Daily Clinical Practice ◽  
Single Centre ◽  
Bioresorbable Vascular Scaffold ◽  
Single Centre Experience ◽  
Vascular Scaffold

scholarly journals Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Mohammad Abdallah Eltahlawi ◽  
Abdel-Aziz Fouad Abdel-Aziz ◽  
Abdel-Salam Sherif ◽  
Khalid Abdel-Azeem Shokry ◽  
Islam Elsayed Shehata
Keyword(s):  
Chronic Total Occlusion ◽  
Bioresorbable Vascular Scaffold ◽  
Total Occlusion ◽  
Intracoronary Imaging ◽  
Group I ◽  
Significant Difference ◽  
Vascular Scaffold ◽  
Long Term Follow Up

Abstract Background We hypothesized that 1st generation everolimus-eluting bioresorbable vascular scaffold (BVS) stent associated with less complication and less restenosis rate than everolimus-eluting stent (EES) in chronic total occlusion (CTO) recanalization guided by intracoronary imaging. Therefore, we aimed to assess the safety and performance of BVS stent in CTO revascularization in comparison to EES guided by intracoronary imaging. Our prospective comparative cross-sectional study was conducted on 60 CTO patients divided into two groups according to type of stent revascularization: group I (EES group): 40 (66.7%) patients and group II (BVS group): 20 (33.3%) patients. All patients were subjected to history taking, electrocardiogram (ECG), echocardiography, laboratory investigation, stress thallium study to assess viability before revascularization. Revascularization of viable CTO lesion guided by intracoronary imaging using optical coherence tomography (OCT). Then, long-term follow-up over 1 year clinically and by multi-slice CT coronary angiography (MSCT). Our clinical and angiographic endpoints were to detect any clinical or angiographic complications during the follow-up period. Results At 6 months angiographic follow-up, BVS group had not inferior angiographic parameters but without statistically significant difference (p = 0.566). At 12 months follow-up, there was no difference at end points between the two groups (p = 0.476). No differences were found at angiographic or clinical follow-up between BVS and EES. Conclusion This study shows that 1st generation everolimus-eluting BVS is non-inferior to EES for CTO revascularization. Further studies are needed to clearly state which new smaller footprint BVS, faster reabsorption, magnesium-based less thrombogenicity, and advanced mechanical properties is under development. We cannot dismiss the efficacy and safety of new BVS technology. Trial registration ZU-IRB#2498/3-12-2016 Registered 3 December 2016, email: [email protected]

scholarly journals Bioresorbable Vascular Scaffold Korean Expert Panel Report

2017 ◽  
Vol 47 (6) ◽  
pp. 795 ◽  
Author(s):  
Jung-Min Ahn ◽  
Duk-Woo Park ◽  
Sung Jin Hong ◽  
Young Keun Ahn ◽  
Joo-Yong Hahn ◽  
...  
Keyword(s):  
Expert Panel ◽  
Bioresorbable Vascular Scaffold ◽  
Panel Report ◽  
Vascular Scaffold
Sign in / Sign up

Export Citation Format

Share Document